Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Ciclopirox (HOE-296; LACQUER; Penlac), a hydroxypyrimidine analog, is an potent, synthetic and broad-spectrum antifungal agent used for topical dermatologic treatment of superficial mycoses. It acts as an iron chelator and also inhibits the membrane transfer system by interrupting the Na+ K+ ATPase. Ciclopirox is currently being investigated as an alternative treatment to ketoconazole for seborrhoeic dermatitis.
ln Vitro |
In an investigation aimed at deciphering the mechanism of Ciclopirox, a number of Saccharomyces cerevisiae mutants were examined and evaluated. According to findings from the interpretation of the effects of the drug treatment and mutation, Ciclopirox may work by interfering with DNA repair, mitotic spindles, and other cell division signals and structures, as well as certain aspects of intracellular transport[2].
A broad-spectrum antifungal with anti-inflammatory qualities, ciclopirox is effective against Malassezia spp., the yeast linked to seborrheic dermatitis[3]. |
|
---|---|---|
ln Vivo |
|
|
Cell Assay |
Sabouraud glucose medium (2%) is used for cell culture growth, and RPMI 2% glucose medium and 2% Sabouraud glucose medium are used for MIC determinations. For cell culture growth curves, 220 mL of 2% Sabouraud glucose medium containing different concentrations of Ciclopirox are inoculated with 105 cells/mL, and the mixture is shaken at 160 rpm and 37 °C for 1-10 hours. Growth is measured photometrically at 630 nm. FeCl3 or 2,2-bipyridine is added to the medium at different concentrations for inhibition studie.
|
|
Animal Protocol |
Different animal organ models including mouse skin wound model, rat kidney model and chicken chorioallantoic membrane model
|
|
References |
Molecular Formula |
C12H17NO2
|
|
---|---|---|
Molecular Weight |
207.27
|
|
Exact Mass |
207.13
|
|
Elemental Analysis |
C, 69.54; H, 8.27; N, 6.76; O, 15.44
|
|
CAS # |
29342-05-0
|
|
Related CAS # |
Ciclopirox olamine;41621-49-2;Ciclopirox olamine;41621-49-2;Ciclopirox-d11;Ciclopirox-d11 sodium
|
|
Appearance |
White to off-white solid powder.
|
|
SMILES |
CC1=CC(=O)N(C(=C1)C2CCCCC2)O
|
|
InChi Key |
SCKYRAXSEDYPSA-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C12H17NO2/c1-9-7-11(13(15)12(14)8-9)10-5-3-2-4-6-10/h7-8,10,15H,2-6H2,1H3
|
|
Chemical Name |
6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 41~100 mg/mL ( 197.8~482.46 mM )
Ethanol : 41 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5%DMSO + Corn oil: 3mg/ml (14.47mM) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.8246 mL | 24.1231 mL | 48.2462 mL | |
5 mM | 0.9649 mL | 4.8246 mL | 9.6492 mL | |
10 mM | 0.4825 mL | 2.4123 mL | 4.8246 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05809297 | Not yet recruiting | Drug: Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer |
Onychomycosis | Universidad Complutense de Madrid | September 1, 2023 | Phase 4 |
NCT02679911 | Completed Has Results |
Drug: Loceryl NL Drug: Ciclopirox NL |
Foot Dermatoses | Galderma R&D | September 2015 | Phase 4 |
NCT00990587 | Completed | Drug: Ciclopirox Olamine | Hematologic Malignancy Acute Lymphocytic Leukemia |
University Health Network, Toronto | October 2009 | Phase 1 |
NCT01646580 | Terminated | Drug: ciclopirox | Dermatomycoses | Ferrer Internacional S.A. | October 2008 | Phase 4 |